PDX Breast Cancer Model WHIM4

Technical Information
Published in Cell Reports, WHIM4 is a highly characterized, triple negative (HER2-, ER-, PR-) PDX model of breast cancer. Derived from a skin metastasis, this line is whole genome sequenced, and possesses a R175H mutation in p53.

Technical Data

Whole Genome Sequenced
Yes
RNA Sequence
No

Tumor Information

Availability
Available
Tumor Site
Metastasis: Skin
Patient Number
4

Patient Demographics

Age at Diagnosis
49
Patient Race
African American
Family History
None

PAM50 Subtype

PAM50 Originating Tumor
Basal
PAM50 Early Passage
Basal
PAM50 Late Passage
Basal

Genotype/Mutations

ER Status
Negative
PR Status
Negative
HER2 Status
Negative
p53 Genotype
R175H
PIK3CA Genotype
WT
ESR1 Genotype
WT
Phosphoprotein Highest Rank
p27_pT198

Pathology

Specimen Type
Core -- abdominal wall recurrence
Clinical Stage, Diagnosis
2B
Pathological Stage
PathCR
Sample Stage
4
Pathology
Ductal
Tumor Grade
3
Metastatic Site List
Bone; Nodes; Lung; Pleura; Liver; Skin; Pericardium
Systemic Treatments
Adj. Herceptin; Gem, Paclitaxel, Herceptin; Capecitabine; Grafted sample for WHIM4; bevacizumab, docetaxel
Overall Survival (months)
37

PAM50 Subtype Expression

PAM50 Subtype Microarray
PDX Breast Cancer Model WHIM4 - PAM50 Subtype Microarray
Microarray showing PAM50 subtype. Unsupervised hierarchical clustering of samples using all genes of the microarrays except the stromal-related genes. The colors of the array tree and the squares below the tree denote the subtype call of each sample. Red, basal-like; pink, HER2-enriched; dark blue, lumenal A; light blue, lumenal B; yellow, Claudin-low. Below the array tree and the subtype identification row, the heatmap of the 50 PAM50 genes as well as selected tight-junction-related genes (E-cadherin [CDH1], claudin 3 [CLDN3], CLDN4, and CLDN7) are shown. The stromal-related genes were identified after a two-class paired SAM was performed with an FDR of 0% between 18 paired progenitor human tumors and xenografts.
PAM50 Microarray Validation
PDX Breast Cancer Model WHIM4 - PAM50 Microarray Validation
Validation of PAM50 microarray. Coclustering of 250 human breast samples representing all the PAM50 intrinsic subtypes and 22 HIM models using the 50 PAM50 genes. Gene expression data of all samples has been obtained using 244K Agilent microarrays.
Claudin Low Signature
PDX Breast Cancer Model WHIM4 - Claudin Low Signature
Microarray of 807 genes that make up the Claudin-low signature. On the right, the expression of each gene (up- or downregulated) of the Claudin-low signature is shown. The two Claudin-low samples (WHIM12 and WHIM17) are identified below the array tree.

ER, HER2 and PR Expression

ER and HER2 Western Blots
PDX Breast Cancer Model WHIM4 - ER and HER2 Western Blots
ER and HER2 protein expression. Tumor lysates from ER-positive (A) and ER-negative (B) WHIM lines were analyzed by western blot to confirm ER and HER2 status. Lysates from ER-negative WHIM lines were also probed with antibodies against the cytokeratin 5/6 (CK 5/6) and CD44 markers. The MCF7 (ER-positive), SKBR3 (ER-negative, HER2-positive) and MDA-MB-231 (ER-negative, CD44-positive) breast cancer cell lines were included as blotting controls.

Circos Plots & Phosphoprotein Expression

Phosphoprotein Expression
PDX Breast Cancer Model WHIM4 - Phosphoprotein Expression
Phosphoprotein expression by RPPA. The RPPA data for WHIM samples and 386 TCGA samples were combined after standardizing the data for each marker (i.e., subtracting the mean and then divided by the standard deviation) in the separate data sets. The combined samples were hierarchically clustered using a Pearson correlation based distance matrix ((1-rho)/2, where rho is the Pearson correlation matrix) and the “ward” linkage based on Ward’s minimum variance. In every case the samples from each WHIM line clustered adjacently, including the two double PDX model isolations (WHIM2 and WHIM5, WHIM20 and WHIM23). This demonstrates that intra-PDX heterogeneity was considerably less than the inter-tumoral heterogeneity in a large RPPA data set and was relatively stable over time and passage.
Protocols & Documents
Reviews

Write Your Own Review

You're reviewing: PDX Breast Cancer Model WHIM4

How do you rate this product? *

 
1 1 star
2 2 star
3 3 star
4 4 star
5 5 star
Quality
Price
Value
Back to top